-
AZD0156: A Decision Framework for ATM Research
2026-09-15
AZD0156 is a selective ATM kinase inhibitor for dissecting DNA damage signaling, repair, and context-dependent cancer vulnerabilities. This article translates mechanistic evidence from high-grade serous ovarian cancer research into a practical framework for interpreting target engagement, combination effects, and assay limitations.
-
Optimized hiPSC Platelet Differentiation: Study Insights
2026-09-15
A 2026 study presents an optimized differentiation scheme that combines higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and enhanced megakaryocyte maturation. The approach shortened production to 19 days, reached 14.9 platelets per starting iPSC, improved functional readouts, and reduced reported costs by 58.3%.
-
Polyethylenimine Linear: PEI MW 40,000 and Endocytosis
2026-09-14
Explore how Polyethylenimine Linear, PEI MW 40,000, connects DNA condensation with the mechanics of cellular uptake. This article translates new single-particle-tracking insights into practical decisions for transient gene expression, assay design, and reproducible transfection.
-
Amikacin Disulfate: From Binding to Assay Design
2026-09-14
Amikacin disulfate is a mechanistically informative semisynthetic aminoglycoside antibiotic for connecting 16S rRNA targeting with orthogonal protein-binding assays. This guide translates lysozyme-complexation findings into practical decisions for antibiotic mechanism of action and resistance research.
-
Recombinant Human FGF-19: Assay Strategy
2026-09-13
Recombinant Human FGF-19 can do more than support routine receptor or proliferation assays. This article presents an evidence-centered strategy for using FGF-19 protein in endocrine signaling and metabolic regulation research while applying mechanistic lessons from WIP1–p38 MAPK studies without overstating cross-domain evidence.
-
Aurora Kinase A in High-Risk Retinoblastoma
2026-09-12
A 2024 study in The American Journal of Pathology identifies Aurora kinase A (AURKA) overexpression as a feature of human retinoblastoma associated with histopathologic high-risk factors and poor chemotherapy response. By integrating patient-tissue analysis with genetic, pharmacologic, cell-based, and xenograft models, the work provides a mechanistic rationale for evaluating AURKA-directed strategies in aggressive or refractory disease.
-
MK-5108 (VX-689) for Aurora A Research
2026-09-11
MK-5108 (VX-689) is a highly selective Aurora A tool for connecting kinase biochemistry with cell-cycle, cancer cell line proliferation assay, and xenograft studies. This workflow shows how to use its potency, solubility profile, and Aurora A-focused biology while avoiding common interpretation and dosing errors.
-
Merbromin as a Mixed-Type SARS-CoV-2 3CLpro Inhibitor
2026-09-11
A high-throughput enzyme screen of approximately 6,000 compounds identified Merbromin as a selective inhibitor of SARS-CoV-2 3CLpro, with kinetic, binding, and docking data supporting mixed-type inhibition. The study provides a useful framework for distinguishing target-selective protease inhibition from nonspecific activity against broad-spectrum proteases.
-
PPARα Inhibits Pyroptosis in Cholestatic Liver Injury
2026-09-10
The reference study identifies a dual anti-pyroptotic mechanism by which PPARα activation protects mice from lithocholic acid-induced cholestatic liver injury. Its findings connect PPARα to both NLRP3/NF-κB signaling and the APAF1/CASPASE-3/GSDME pathway, providing a framework for evaluating PPARα-directed interventions in liver-injury models.
-
SU5416 (Semaxanib) for Angiogenesis Research
2026-09-10
Build more discriminating angiogenesis experiments with SU5416 (Semaxanib), a selective VEGFR2 inhibitor suited to VEGF-response, endothelial proliferation, and tumor vascularization studies. This workflow also shows how to separate receptor-driven effects from normoxic HIF1α and metabolic signaling uncovered in primary vascular cells.
-
TGF-β, Sca-1, and Mammary Cell Plasticity
2026-09-09
The reference study shows that TGF-β regulates Sca-1 expression while reshaping the plasticity and tumor-initiating potential of pre-neoplastic mammary epithelial cells. Its key contribution is the distinction between endogenous Smad2/3/4-dependent regulation and exogenous TGF-β-driven Sca-1 loss, which appears to use a different mechanism.
-
Amyloid Beta-Peptide (1-40): Practical Workflows
2026-09-09
Build more reproducible amyloid fibril formation studies and neurotoxicity mechanism investigations with a controlled Aβ40 workflow. This guide connects peptide preparation, calcium-sensitive membrane assays, optical readouts, and cell-based validation while emphasizing timing, aggregation state, and troubleshooting.
-
Amphotericin B in Membrane-Aware Cell Assays
2026-09-08
Amphotericin B is more than a fungal growth inhibitor: it is a powerful probe of sterol-dependent membrane failure, inflammatory signaling, and assay vulnerability. This article connects its mechanism to orthogonal mammalian-cell readouts and derives practical assay lessons from a canine epithelial-cell toxicology study.
-
BCECF: Ratiometric Extracellular pH Probe
2026-09-08
BCECF is a cell-impermeant, dual-excitation fluorescent pH probe for quantitative extracellular and accessible-compartment pH measurement. Its approximate pKa of 6.98 and 535 nm emission ratio support assays of ion transport, cellular metabolism, acid-base homeostasis, and microenvironmental pH regulation.
-
SU5416 (Semaxanib): Reliable Assay Design
2026-09-07
A scenario-based guide to using SU5416 (Semaxanib), SKU A3847, in endothelial, viability, proliferation, and angiogenesis workflows. It connects mechanism, solvent control, concentration planning, model interpretation, and practical product-selection criteria to improve experimental reproducibility.